
Opinion|Videos|June 3, 2024
Alzheimer’s Disease Pipeline
Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please provide an overview of robust Alzheimer’s pipeline and many disease modifying therapies under investigation.
- Discuss novel and emerging treatments that are most advanced in clinical studies or have promising data:
- Valiltramiprosate (ALZ-801,inhibits amyloid oligomer formation, oral)
- ALN-APP (RNAi therapeutic)
- Blarcamesine (sigma-1 and muscarinic receptors ligand)
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
4
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
5